Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease

Rodger J. Elble, Oksana Suchowersky, Stephanie Shaftman, William J. Weiner, Peng Huang, Barbara Tilley

Research output: Contribution to journalArticlepeer-review


We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.

Original languageEnglish (US)
Pages (from-to)1082-1086
Number of pages5
JournalMovement Disorders
Issue number8
StatePublished - Jun 15 2010


  • Bias
  • Clinical trial
  • Parkinson's disease
  • Unified Parkinson's disease rating scale

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease'. Together they form a unique fingerprint.

Cite this